4.5 Article

Serotonergic Function and Treatment of Behavioral and Psychological Symptoms of Frontotemporal Dementia

Journal

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
Volume 20, Issue 9, Pages 789-797

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JGP.0b013e31823033f3

Keywords

Citalopram; frontotemporal dementia; serotonin

Funding

  1. Canadian Institutes of Health Research [CIHR MT13129]
  2. Alzheimer Society of Canada [07-48]
  3. Pfizer
  4. Janssen-Ortho
  5. Novartis
  6. Lundbeck
  7. Wyeth
  8. Novartis Pharmaceuticals
  9. Myriad Pharmaceuticals
  10. Roche
  11. GlaxoSmithKline
  12. Novartis Pharmaceutical
  13. Schering-Plough
  14. Elan
  15. Wyeth Pharmaceuticals
  16. Bristol-Myers Squibb
  17. Canadian Institute of Health Research
  18. Alzheimer Society of Canada

Ask authors/readers for more resources

Objectives: The purposes of this study were first, to evaluate the effectiveness of citalopram in treating behavioral disturbances in frontotemporal dementia (FTD) subjects and second, to determine whether an association exists between serotonergic function, as determined by a neuroendocrine challenge, and treatment response. Design: Single-dose citalopram (30 mg per os) challenge followed by a 6-week open-label study. Setting: Outpatients referred to memory clinics. Participants: Fifteen patients suffering from FTD with severe behavioral and psychological symptoms of dementia. Intervention: Following citalopram challenge, all patients were treated with citalopram titrated to a target dose of 40 mg once daily. Measurements: Behavioral disturbances, using the Neuropsychiatric Inventory (NPI) (primary outcome) and Frontal Behavioural Inventory (secondary outcome), were assessed. Change in prolactin concentration following citalopram challenge was used as an index of central serotonergic response. Results: Citalopram treatment was effective in treating behavioral symptoms, with significant decreases in NPI total score (F-[2,F- 28] = 6.644, p = 0.004), disinhibition (F-[2,F- 28] = 4.030, p = 0.029), irritability (F-[2,F- 28] = 7.497, p = 0.003) and depression (F-[2,F- 28] = 3.467, p = 0.045) scores over the 6 weeks. Significant improvement in Frontal Behavioural Inventory scores suggested that citalopram was also effective in the treatment of behaviors specific to FTD. A lower change score in concentration of prolactin was significantly positively correlated with greater improvement in the total NPI score from baseline to endpoint (r = 0.687, p = 0.005). A blunted response to a citalopram challenge, implying a dysfunctional serotonergic system, predicted a more positive treatment outcome. Conclusions: The results suggest that despite the endogenous serotonin deficiency of FTD, citalopram treatment may be effective in targeting the behavioral disturbances characteristic of FTD. (Am J Geriatr Psychiatry 2012; 20:789-797)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available